Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Disease prevention trials in IBD: feasibility to future outlook

Nature Reviews Gastroenterology & Hepatology (2024)Cite this article

Subjects

Therapeutic advances in inflammatory bowel disease (IBD) have been universally directed towards patients with established disease to control inflammation, ameliorate symptoms and hinder disease progression, but preventing IBD development or delaying its onset are highly attractive. This Comment discusses the emerging approaches and future promises of interventional disease prevention trials in IBD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Timing of prevention trials in the natural history of IBD.

References

  1. Rudbaek, J. J. et al. Deciphering the different phases of preclinical inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 21, 86–100 (2024).

    Article  PubMed  Google Scholar 

  2. Craig, P. et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 337, a1655 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ananthakrishnan, A. N. et al. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol. Hepatol. 7, 666–678 (2022).

    Article  PubMed  Google Scholar 

  4. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05211518 (2024).

  5. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05566587 (2022).

  6. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03950336 (2024).

  7. Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838–849 (2024).

    Article  CAS  PubMed  Google Scholar 

  9. Rech, J. et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403, 850–859 (2024).

    Article  CAS  PubMed  Google Scholar 

  10. Felix, P. A. O., Sampaio, A. L., Silva, B. L. & Viana, A. L. P. Early intervention in psoriasis: where do we go from here? Front. Med. 9, 1027347 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, INFINY Institute, Inserm NGERE, CHRU Nancy, Nancy, France

    Sailish Honap & Laurent Peyrin-Biroulet

  2. Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, London, UK

    Sailish Honap

  3. School of Immunology and Microbial Sciences, King’s College London, London, UK

    Sailish Honap

  4. CIC, Epidémiologie Clinique, Université de Lorraine, CHRU Nancy, Inserm, Nancy, France

    Nelly Agrinier

  5. INSPIIRE, Université de Lorraine, Inserm, Nancy, France

    Nelly Agrinier

  6. Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy

    Silvio Danese

Authors
  1. Sailish Honap
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nelly Agrinier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvio Danese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurent Peyrin-Biroulet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Peyrin-Biroulet.

Ethics declarations

Competing interests

S.H. served as a speaker, a consultant, an advisory board member and/or has received grants from Pfizer, Janssen, AbbVie, Takeda, Lilly, Ferring, and Pharmacosmos. S.D. has served as a speaker, consultant and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. L.P.-B. reports consulting fees from Abbvie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, BMS, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, Par’ Immune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx and Ysopia; reports grants from Celltrion, Fresenius Kabi, Medac, MSD and Takeda; reports lecture fees from Abbvie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots and Viatris; and reports travel support from Abbvie, Amgen, Celltrion, Connect Biopharm, Ferring, Galapagos, Genentech, Gilead, Gossamer Bio, Janssen, Lilly, Medac, Morphic, MSD, Pfizer, Sandoz, Takeda, Thermo Fischer and Tillots. N.A. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honap, S., Agrinier, N., Danese, S. et al. Disease prevention trials in IBD: feasibility to future outlook. Nat Rev Gastroenterol Hepatol (2024). https://doi.org/10.1038/s41575-024-00984-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41575-024-00984-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing